Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 4/20 | 0.40 |
| ▸ | ESR1 | P03372 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3889862 | 1.00 | SLC5A1 (0.40) | SLC5A1ESR1CA12AKR1B10CA1 | |
| SCHEMBL1131257 | 0.86 | CA12 (0.43) | SLC5A1ESR1CA12CA1CA2 | |
| SCHEMBL1131251 | 0.86 | CA12 (0.43) | SLC5A1ESR1CA12CA1CA2 | |
| SCHEMBL1131668 | 0.83 | KDM4E (0.44) | PKMCRACR2A | |
| SCHEMBL1131667 | 0.83 | KDM4E (0.44) | PKMCRACR2A | |
| SCHEMBL3895793 | 0.81 | SLC5A1 (0.39) | SLC5A1MIFEPHX2CRACR2A | |
| SCHEMBL1131260 | 0.81 | SLC5A1 (0.39) | SLC5A1MIFEPHX2CRACR2A | |
| SCHEMBL1131253 | 0.78 | SLC5A1 (0.38) | SLC5A1MIFEPHX2CRACR2A | |
| SCHEMBL1131754 | 0.74 | KDM4E (0.42) | SLC5A1CRACR2A | |
| SCHEMBL1131839 | 0.74 | KDM4E (0.42) | SLC5A1CRACR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663105-A4 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2009-04-15 | — | — | EP | disclosed |
| US-7112601-B2 | Cycloalkyl heterocycles for treating hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1663105-A2 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | Bristol-Myers Squibb Company (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005034850-A2 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050075376-A1 | Cycloalkyl heterocycles for treating Hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075376-A1 | Cycloalkyl heterocycles for treating Hepatitis C virus | HCCS, NSUN2, HAVCR2 | SLC5A1 4333/4885ESR1 4488/4885CA12 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.